Use caution in elderly higher frequency of take renal function into consideration before initiating. Dispense in tight, light-resistant container as defined in the USP, with child-resistant closure as required. In December 2007, the Company entered into worldwide licensing and collaboration agreement with Merck KGaA for the research, development and commercialization of the Company TLR9 agonists for the treatment of cancer, excluding cancer vaccines. The Company has identified DNA-based compounds that act as antagonists of kopa torsk ribavirin TLR7 and TLR9 and has evaluated these compounds in preclinical mouse models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis and colitis. Give by oxygen hood from SPAG-2 unit to infant who isn mechanically ventilated. Additional testing should be performed periodically during therapy.